Larimar Therapeutics, Inc.

The US Food & Drug Administration’s inaugural class of applications for its START rare disease pilot program includes three early-stage gene therapy programs intended to treat pediatric diseases, incl

Biomedtracker’s latest report on biopharmaceutical company fundraising shows a 25.1% decline in year-over-year dollars raised, from $17.5bn in the fourth quarter of 2022 to $13.1bn in Q4 of 2023. Foll

Only days after announcing a plan to reduce expenses by $1bn, Biogen, Inc. reeled in the third-largest biopharma M&A deal of 2023, agreeing to pay $7.3bn on 28 July for Reata Pharmaceuticals, Inc.

Third Harmonic Bio launched an initial public offering on 14 September that marked the first IPO in the US by a biopharmaceutical company in four months to raise more than $100m. In fact, the last th